Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant

Phase 2TerminatedNCT01699581

Greg Monohan35 enrolled

Overview

Nestle Impact has shown efficacy in multiple surgical trials in relation to improving hospital length of stay and infection rate. 1 dose of Nestle Impact Advanced Recovery will be taken orally three times a day beginning on the morning following stem cell transplant and will continue until the day of hospital discharge.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hodgkin's Lymphoma Multiple Myeloma Non-Hodgkin's Lymphoma

Interventions

Nestle Impact Advanced RecoveryDIETARY_SUPPLEMENT

dose of Nestle Impact Advanced Recovery orally three times a day beginning on the morning following stem cell transplant and continued until the day of hospital discharge.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients receiving an autologous stem cell transplant using the preparative regimens of BEAM (Carmustine, Etoposide, Cytarabine, Melphalan), Melphalan 140mg/m2, or Melphalan 200mg/m2 * Any prior diet or supplement will be allowed. * Age \>18 years. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * History of allergic reactions attributed to compounds of similar chemical or biologic composition to Nestle Impact including fish oil.

Locations (1)

University of Kentucky, Markey Cancer Center

Lexington, Kentucky, United States

Outcomes

Primary Outcomes

Hospital length of stay

Time frame: Particpants will be followed for 14 days, the average length of time from stem cell infusion until dischcarge

Days to engraftment

Time frame: Particpants will be followed for 14 days, the average length of time from stem cell infusion until dischcarge

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.